DRAP Requires Batch Testing of Cough Syrup Ingredients Before Use
The regulator says manufacturers must test glycerine, sorbitol and propylene glycol for toxic contaminants before production, document results and withhold oral liquid medicines from release until verification is complete.
ISLAMABAD, (Pakistan Point News - 22nd Nov, 2026) The Drug Regulatory Authority of Pakistan (DRAP) has directed pharmaceutical manufacturers to strengthen quality control and conduct mandatory testing of raw materials used in cough syrups and other oral liquid medicines to prevent contamination with toxic chemicals.
In an advisory issued ahead of the winter season, DRAP highlighted the need for strict compliance with Good Manufacturing Practices (GMP), given the expected increase in demand and production of cough syrups and other oral liquid preparations.
The authority directed manufacturers to procure critical raw materials, including glycerine, sorbitol and propylene glycol, only from qualified and approved suppliers in accordance with current GMP requirements.
Manufacturers have also been instructed to conduct mandatory pre-use testing of every procured batch of these ingredients to detect possible contamination with Diethylene Glycol (DEG) and Ethylene Glycol (EG) before their use in production.
Companies lacking in-house testing facilities have been advised to use the services of the Central Drug Laboratory (CDL), Karachi, for the required analysis.
DRAP further directed manufacturers to verify and properly document laboratory test results and Certificates of Analysis (CoA) alongside Batch Manufacturing Records (BMR) to ensure traceability and product quality.
The advisory makes it clear that oral liquid preparations containing these ingredients must not be released until the required testing and verification have been completed and documented in the batch records.
Manufacturers have also been directed to maintain complete records of raw material procurement, supplier details, laboratory test results and batch utilisation for regulatory inspection.
DRAP warned that failure to comply with the directives could invite stringent regulatory action under the Drugs Act, 1976, the DRAP Act, 2012, and rules framed thereunder.
395/
内容来自 UrduPoint News,版权归原作者所有。
阅读原文 ↗